DGAP-News

Biotest AG: Further preclinical studies emphasise the potential of Indatuximab Ravtansine (BT-062) in solid tumours

DGAP-News: Biotest AG / Key word(s): Research Update
Biotest AG: Further preclinical studies emphasise the potential of
Indatuximab Ravtansine (BT-062) in solid tumours

24.10.2014 / 10:30

---------------------------------------------------------------------

PRESS RELEASE

Further preclinical studies emphasise the potential of Indatuximab
Ravtansine (BT-062) in solid tumours

- Antibody-drug conjugate shows high efficacy in an animal model in the
treatment of bladder, breast, pancreatic and other tumours.

- Complete remission achieved in some treatment-refractory tumours.

- Presentation of the results at the World ADC specialist conference in
San Diego.

Dreieich, 24 October 2014. Biotest has further results from preclinical
studies of Indatuximab Ravtansine (BT-062) in various solid tumours. The
studies were undertaken by Oncotest GmbH in Freiburg, an independent
research laboratory. They exhibit efficacy that can be "classified as
unusually good", according to a statement by the director, Prof. Dr.
Heinz-Herbert Fiebig. "I have personally never yet seen such an outstanding
effect on this scale," Prof. Fiebig continued.

Indatuximab Ravtansine was tested in vivo on human carcinomas of the
bladder, breast, lung, prostate and pancreas and on head and neck tumours.
A mouse model specially developed by Oncotest was used.
The tumour size diminished markedly under the therapy. 9 out of 14 tumours
completely disappeared, some of which had not responded previously to
standard therapy. These new studies, which concluded recently, confirm the
results of previous preclinical studies published in 2012 and emphasise the
high potential of Indatuximab Ravtansine.

"As an independent research institute with over 30 years' experience,
Oncotest has a very good overview of current development projects in
haematology and oncology. Classifying the test results with Indatuximab
Ravtansine as extraordinarily good is therefore a particular confirmation
for us to push ahead with development in these tumour indications", says
Prof. Gregor Schulz, CEO of Biotest AG. Biotest will present the recent
results at the World ADC conference, which takes place in San Diego from 26
to 29 October.

In March 2014 Biotest started a clinical phase I/IIa study in which the
safety and anti-tumour activity of Indatuximab Ravtansine are being
investigated in patients with triple receptor-negative metastatic breast
cancer and patients with metastatic bladder cancer, who have the CD138